Nuevolution AS

Nuevolution: Conference Call to Discuss the Strategic Collaboration with Almirall

STOCKHOLM--(BUSINESS WIRE)--

Nuevolution AB (publ) (NUE.ST) announce that the company’s executive management will host a conference call and webcast to discuss the strategic collaboration with Almirall on Monday 12 December at 14:00 CET. Access to the event can be obtained as follows:

LIVE access on Monday 12 December at 14:00 CET

Telephone numbers:

SE: +46 85 664 2690

DK: +45 3544 5575

UK: +44 20 3008 9802

US: +1 855 831 5945

Webcast will be available at www.nuevolution.com in the Investors section and at www.financialhearings.com.

REPLAY access

Webcast replay will be available at www.nuevolution.com in the Investors section and at www.financialhearings.com.

About Nuevolution

Nuevolution AB (publ) is a leading small molecule drug discovery biotech company founded in 2001, headquartered in Copenhagen, Denmark. Nuevolution partners its proprietary discovery platform and programs with pharmaceutical and biotechnology companies to seek future benefit of patients in need of novel medical treatment options. Nuevolution’s internal programs are focused on therapeutically important targets within inflammation, oncology and immuno-oncology.

This information is information that Nuevolution AB (publ) is obliged to make public pursuant to the Securities Market Act. The information was sent for publication, through the agency of the contact persons set out above, on Monday 12 December 2016, 11:30 (CET).

Nuevolution AB (publ) is listed at Nasdaq First North Premier in Stockholm, Sweden (ticker: NUE.ST). Redeye AB acts as Certified Adviser to Nuevolution AB (publ). More information about Nuevolution can be found on: www.nuevolution.com

This information was brought to you by Cision http://news.cision.com

EN
12/12/2016

Underlying

Nuevolution AS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nuevolution AS

Daniel Wilkinson
  • Daniel Wilkinson
NUEVOLUTION AS

Nuevolution - Amgen offers SEK32.50/share in cash

Amgen has announced a recommended cash offer for Nuevolution’s shares of SEK32.50/share, valuing the company at approximately SEK1,610m (US$167m). The offer represents a 169% premium to the closing price (SEK12.10) on 21 May (the day before the announcement) and a 69% premium to the highest trading price (SEK19.26) over the 52-week period (before 21 May 2019). Nuevolution’s board has unanimously recommended that shareholders accept the offer. The offer is not subject to any financing conditi...

05/29/19 May 29, 2019 3 EN
Daniel Wilkinson
  • Daniel Wilkinson
NUEVOLUTION AS

Nuevolution - Small molecules, big ambitions

Positive progress in Nuevolution’s RORγt partnership with Almirall has triggered a €1m milestone payment (SEK10.5m) and we continue to forecast that it will enter the clinic in 2019. FY18 was defined by the progress in the Amgen partnership as it opted in for two oncology programmes, further validating Nuevolution’s Chemetics technology. In Nuevolution’s BET-BD1 programme, a development candidate (NUE20798) has been nominated; data in animal cancer models highlight that it may have syne...

03/19/19 March 19, 2019 15 EN
NUEVOLUTION AS

Nuevolution - Pipeline and partnerships continue to strengthen

With the completion of the up-listing to the Nasdaq Stockholm main market and the successful gross SEK110m capital raise, Nuevolution continues to strengthen both its investor base and financial position. Amgen’s opt-in on the first programme in its multi-target collaboration and the identification of much sought-after small-molecule IL-17A inhibitors continue to validate Nuevolution’s Chemetics technology. Its transition to a clinical asset-focused company continues with the Almirall RORγt...

09/25/18 September 25, 2018 9 EN
Daniel Wilkinson
  • Daniel Wilkinson
NUEVOLUTION AS

Nuevolution - Pipeline and strategic execution drives prospects

Nuevolution’s 2017 was defined by internal progress of the RORγt inhibitor and BET-BD1 programmes (expected to be clinically ready in 2019). In 2018 we anticipate value will be driven by new and existing partners, for example we expect Almirall to initiate a RORγt inhibitor Phase I trial in late 2018, making it the first Nuevolution product candidate to enter the clinic. In addition to existing collaborations, a new partnership is anticipated by Nuevolution in the next three to nine months. ...

03/15/18 March 15, 2018 16 EN
Daniel Wilkinson
  • Daniel Wilkinson
NUEVOLUTION AS

Nuevolution - On the road to becoming a clinical company

July to September 2017 results highlight the continued progression of Nuevolution into a clinical company. Ongoing partnerships with Almirall, Amgen and Janssen continue to advance as we expect and we anticipate that Almirall’s RORγt inhibitor programme will be the first Nuevolution asset to enter the clinic (in dermatology and psoriatic arthritis), which we forecast for H218/H119. Lead assets in the internal pipeline are nearing clinical readiness and Nuevolution anticipates a new partnershi...

11/24/17 November 24, 2017 3 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch